{"id":2605,"date":"2018-03-28T17:44:26","date_gmt":"2018-03-28T12:14:26","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2605"},"modified":"2021-07-24T12:56:58","modified_gmt":"2021-07-24T07:26:58","slug":"takeda-acquisition-shire-raises-share-25-percent","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/takeda-acquisition-shire-raises-share-25-percent","title":{"rendered":"Takeda acquisition on Shire raises its share by 25 percent"},"content":{"rendered":"<p style=\"text-align: justify;\">Takeda revealed on Wednesday that it is thinking to obtain Shire, which led to rise in its share by 25 percent. It also revealed that there has been no approach made to Shire&#8217;s board and the proposal is at a &#8220;preparatory and exploratory&#8221; stage. No information about the investment was revealed by the Japanese drug makers. Takeda after acquiring Shire will flourish in the market of therapeutic areas of oncology, gastrointestinal disorders and neuroscience. The acquisition of Shire\u2019s rare-disease franchise will give an upper hand to Takeda and will pace up its path to become the pioneer in specialised medicine. This will be also profitable to the Shire as this would increase Shire market opportunities in the US. According to the UK acquisition regulations Takeda should give the final decision about its Shire acquisition by April 25. The other<a href=\"https:\/\/www.delveinsight.com\/\"> pharma<\/a> companies such as AbbVie, <a href=\"https:\/\/www.novartis.in\/\">Novartis<\/a>, Pfizer will still be the part of the bidding process which might lead to higher pricing in the bidding race.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Takeda revealed on Wednesday that it is thinking to obtain Shire, which led to rise in its share by 25 percent. It also revealed that there has been no approach made to Shire&#8217;s board and the proposal is at a &#8220;preparatory and exploratory&#8221; stage. No information about the investment was revealed by the Japanese drug [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2733,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[56,253,423,427,460,554],"industry":[17225],"therapeutic_areas":[17239,17245,17228],"class_list":["post-2605","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-abbvie","tag-gastrointestinal-disorders","tag-novartis","tag-oncology","tag-pfizer","tag-takeda","industry-pharmaceutical","therapeutic_areas-gastroenterology","therapeutic_areas-neurology","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Takeda acquisition on Shire raises its share by 25 percent - DELVEINSIGHT<\/title>\n<meta name=\"description\" content=\"Takeda acquisition on Shire raises its share by 25 percent . Look inside for more detailed information....................\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/takeda-acquisition-shire-raises-share-25-percent\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Takeda acquisition on Shire raises its share by 25 percent - DELVEINSIGHT\" \/>\n<meta property=\"og:description\" content=\"Takeda acquisition on Shire raises its share by 25 percent . Look inside for more detailed information....................\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/takeda-acquisition-shire-raises-share-25-percent\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-03-28T12:14:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/05\/15171018\/https_2F2Fs3-ap-northeast-1.amazonaws.com2Fpsh-ex-ftnikkei-3937bb42Fimages2F02F42F62F82F13588640-9-eng-GB2F20180406-takeda-pharmaceutical-02-logo-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1440\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Takeda acquisition on Shire raises its share by 25 percent - DELVEINSIGHT","description":"Takeda acquisition on Shire raises its share by 25 percent . Look inside for more detailed information....................","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/takeda-acquisition-shire-raises-share-25-percent","og_locale":"en_US","og_type":"article","og_title":"Takeda acquisition on Shire raises its share by 25 percent - DELVEINSIGHT","og_description":"Takeda acquisition on Shire raises its share by 25 percent . Look inside for more detailed information....................","og_url":"https:\/\/www.delveinsight.com\/blog\/takeda-acquisition-shire-raises-share-25-percent","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-03-28T12:14:26+00:00","article_modified_time":"2021-07-24T07:26:58+00:00","og_image":[{"width":2560,"height":1440,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/05\/15171018\/https_2F2Fs3-ap-northeast-1.amazonaws.com2Fpsh-ex-ftnikkei-3937bb42Fimages2F02F42F62F82F13588640-9-eng-GB2F20180406-takeda-pharmaceutical-02-logo-scaled.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/takeda-acquisition-shire-raises-share-25-percent","url":"https:\/\/www.delveinsight.com\/blog\/takeda-acquisition-shire-raises-share-25-percent","name":"Takeda acquisition on Shire raises its share by 25 percent - DELVEINSIGHT","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/takeda-acquisition-shire-raises-share-25-percent#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/takeda-acquisition-shire-raises-share-25-percent#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/05\/15171018\/https_2F2Fs3-ap-northeast-1.amazonaws.com2Fpsh-ex-ftnikkei-3937bb42Fimages2F02F42F62F82F13588640-9-eng-GB2F20180406-takeda-pharmaceutical-02-logo-scaled.jpg","datePublished":"2018-03-28T12:14:26+00:00","dateModified":"2021-07-24T07:26:58+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Takeda acquisition on Shire raises its share by 25 percent . Look inside for more detailed information....................","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/takeda-acquisition-shire-raises-share-25-percent"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/takeda-acquisition-shire-raises-share-25-percent#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/05\/15171018\/https_2F2Fs3-ap-northeast-1.amazonaws.com2Fpsh-ex-ftnikkei-3937bb42Fimages2F02F42F62F82F13588640-9-eng-GB2F20180406-takeda-pharmaceutical-02-logo-scaled.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/05\/15171018\/https_2F2Fs3-ap-northeast-1.amazonaws.com2Fpsh-ex-ftnikkei-3937bb42Fimages2F02F42F62F82F13588640-9-eng-GB2F20180406-takeda-pharmaceutical-02-logo-scaled.jpg","width":2560,"height":1440,"caption":"takeda"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/05\/15171018\/https_2F2Fs3-ap-northeast-1.amazonaws.com2Fpsh-ex-ftnikkei-3937bb42Fimages2F02F42F62F82F13588640-9-eng-GB2F20180406-takeda-pharmaceutical-02-logo-scaled.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">AbbVie<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">gastrointestinal disorders<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Novartis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Oncology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Takeda<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AbbVie<\/span>","<span class=\"advgb-post-tax-term\">gastrointestinal disorders<\/span>","<span class=\"advgb-post-tax-term\">Novartis<\/span>","<span class=\"advgb-post-tax-term\">Oncology<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>","<span class=\"advgb-post-tax-term\">Takeda<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Mar 28, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Mar 28, 2018 5:44 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2605","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2605"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2605\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2733"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2605"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2605"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2605"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2605"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2605"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}